

## Supplementary Documents [IFRS]

Financial results for the first six months of the fiscal year 2022 (FY2022)

### Astellas Pharma Inc.

- Q2/FY2022 Financial Results
  - Six months ended September 30, 2022
  - Three months ended September 30, 2022
- Pipeline list

#### Cautionary Notes

*In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.*

## [Six months ended September 30, 2022]

### 1. Consolidated Results (Full Basis)

Unit: B¥

	FY21 APR. - SEP.	FY22 APR. - SEP.	Change	Change (%)
Revenue	651.7	762.2	110.5	17.0%
Cost of sales	124.7	151.7	26.9	21.6%
Ratio to Revenue	19.1%	19.9%		
Gross profit	526.9	610.5	83.6	15.9%
SG&A expenses	270.5	308.0	37.4	13.8%
Ratio to Revenue	41.5%	40.4%		
XTANDI co-promotion fee in United States	71.1	89.7	18.6	26.1%
Personnel expenses	96.0	104.8	8.8	9.2%
Advertising and Sales Promotion and Other	103.4	113.5	10.1	9.8%
R&D expenses	119.1	139.2	20.1	16.9%
Ratio to Revenue	18.3%	18.3%		
Amortisation of intangible assets	12.4	20.0	7.6	61.3%
Gain on divestiture of intangible assets	-	0.2	0.2	-
Share of profit (loss) of investments accounted for using equity method	0.3	1.8	1.5	477.8%
Other income	2.8	16.2	13.4	470.7%
Net foreign exchange gains	2.3	13.9	11.6	506.8%
Fair value remeasurements on contingent consideration	-	1.5	1.5	-
Other expense	38.0	41.7	3.8	9.9%
Impairment losses	26.1	22.8	-3.3	-12.6%
Restructuring costs	2.5	1.1	-1.4	-56.0%
Fair value remeasurements on contingent consideration	8.7	15.8	7.1	81.6%
Operating profit	90.2	119.9	29.7	33.0%
Ratio to Revenue	13.8%	15.7%		
Finance income	1.9	4.5	2.6	137.9%
Finance expenses	3.0	3.9	0.9	31.4%
Profit before tax	89.1	120.5	31.4	35.2%
Ratio to Revenue	13.7%	15.8%		
Income tax expense	17.5	24.0	6.6	37.6%
Profit	71.6	96.4	24.8	34.7%
Ratio to Revenue	11.0%	12.7%		
Comprehensive income	70.1	243.7	173.6	247.8%

	Initial Forecasts FY22 Full Year	Revised Forecasts FY22 Full Year	Change from FY21 Change (%)
FY21 Full Year	1,296.2	1,443.0	18.0%
	253.0	1,529.0	
	19.5%		
	1,043.2		
	548.8	598.0	17.0%
	42.3%	642.0	
	139.3	41.4%	42.0%
	191.4	182.0	186.0
	218.1		33.5%
	246.0	254.0	278.0
	19.0%	17.6%	18.2%
	28.3		13.0%
	24.2		
	0.5		
	15.3		
	8.2		
	5.4		
	104.3		
	74.9		
	19.6		
	7.0		
	155.7	269.0	269.0
	12.0%	18.6%	17.6%
	6.1		
	4.9		
	156.9	267.0	267.0
	12.1%	18.5%	17.5%
	32.8		
	124.1	208.0	208.0
	9.6%	14.4%	13.6%
	208.1		67.6%

## 2. Consolidated Results (Core Basis)

Unit: B¥

	FY21 APR. - SEP.	FY22 APR. - SEP.	Change	Change (%)
Revenue	651.7	762.2	110.5	17.0%
Cost of sales	124.7	151.7	26.9	21.6%
Ratio to Revenue	19.1%	19.9%		
Gross profit	526.9	610.5	83.6	15.9%
SG&A expenses	270.5	308.0	37.4	13.8%
Ratio to Revenue	41.5%	40.4%		
XTANDI co-promotion fee in United States	71.1	89.7	18.6	26.1%
Personnel expenses	96.0	104.8	8.8	9.2%
Advertising and Sales Promotion and Other	103.4	113.5	10.1	9.8%
R&D expenses	119.1	139.2	20.1	16.9%
Ratio to Revenue	18.3%	18.3%		
Amortisation of intangible assets	12.4	20.0	7.6	61.3%
Gain on divestiture of intangible assets	-	0.2	0.2	-
Share of profit (loss) of investments accounted for using equity method	0.3	1.8	1.5	477.8%
Operating profit	125.3	145.4	20.1	16.0%
Ratio to Revenue	19.2%	19.1%		
Finance income	1.9	4.5	2.6	137.9%
Finance expenses	3.0	3.9	0.9	31.4%
Profit before tax	124.2	146.0	21.8	17.5%
Ratio to Revenue	19.1%	19.2%		
Income tax expense	25.5	26.0	0.5	2.1%
Profit	98.8	120.0	21.2	21.5%
Ratio to Revenue	15.2%	15.7%		

	Initial Forecasts	Revised Forecasts	Change from FY21
	FY22 Full Year	FY22 Full Year	Change (%)
FY21 Full Year	1,296.2	1,443.0	18.0%
	253.0	1,529.0	
	19.5%		
	1,043.2		
	548.8	598.0	17.0%
	42.3%	642.0	
	41.4%	42.0%	
	139.3	182.0	33.5%
	191.4	186.0	
	218.1		
	246.0	254.0	13.0%
	19.0%	278.0	
	17.6%	18.2%	
	28.3		
	24.2		
	0.5		
	244.7	290.0	18.5%
	18.9%	290.0	
	20.1%	19.0%	
	6.1		
	4.9		
	245.9		
	19.0%		
	55.4		
	190.6	223.0	17.0%
	14.7%	223.0	
		14.6%	

## 3. Exchange Rate

Unit: yen

	FY21 APR. - SEP.Ave.	FY22 APR. - SEP.Ave.	FY21 End	FY22 Q2 End
USD/Yen	110	134	122	145
EUR/Yen	131	139	135	142

	Initial Forecasts	Revised Forecasts
	FY22 Full Year	FY22 Full Year
FY21 Full Year	112	137
	131	139

\* Fx impacts: Revenue +84.3 billion yen and Core operating profit +16.0 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY21 APR. - SEP.			FY22 APR. - SEP.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
<b>Revenue</b>	<b>651.7</b>	-	<b>651.7</b>	<b>762.2</b>	-	<b>762.2</b>
Cost of sales	124.7	-	124.7	151.7	-	151.7
<b>Gross profit</b>	<b>526.9</b>	-	<b>526.9</b>	<b>610.5</b>	-	<b>610.5</b>
SG&A expenses	270.5	-	270.5	308.0	-	308.0
R&D expenses	119.1	-	119.1	139.2	-	139.2
Amortisation of intangible assets	12.4	-	12.4	20.0	-	20.0
Gain on divestiture of intangible assets	-	-	-	0.2	-	0.2
Share of profit (loss) of investments accounted for using equity method	0.3	-	0.3	1.8	-	1.8
Other income *	2.8	-2.8	-	16.2	-16.2	-
Other expenses *	38.0	-38.0	-	41.7	-41.7	-
<b>Operating profit</b>	<b>90.2</b>	<b>35.1</b>	<b>125.3</b>	<b>119.9</b>	<b>25.5</b>	<b>145.4</b>
Finance income	1.9	-	1.9	4.5	-	4.5
Finance expenses	3.0	-	3.0	3.9	-	3.9
<b>Profit before tax</b>	<b>89.1</b>	<b>35.1</b>	<b>124.2</b>	<b>120.5</b>	<b>25.5</b>	<b>146.0</b>
Income tax expense	17.5	8.0	25.5	24.0	2.0	26.0
<b>Profit</b>	<b>71.6</b>	<b>27.1</b>	<b>98.8</b>	<b>96.4</b>	<b>23.5</b>	<b>120.0</b>

\* "Other income" and "Other expenses" are excluded from Core basis results.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

## 5. Revenue by Region

Unit: B¥

	FY21 APR. - SEP.	FY22 APR. - SEP.	Change	Change (%)
Revenue	651.7	762.2	110.5	17.0%
Japan	130.5	133.3	2.8	2.1%
Ratio to Revenue	20.0%	17.5%		
United States	270.1	328.3	58.2	21.5%
Ratio to Revenue	41.5%	43.1%		
Established Markets	157.4	180.1	22.8	14.5%
Ratio to Revenue	24.1%	23.6%		
Greater China	33.1	45.0	12.0	36.2%
Ratio to Revenue	5.1%	5.9%		
International Markets	55.3	63.3	8.0	14.5%
Ratio to Revenue	8.5%	8.3%		
Others	5.3	12.1	6.8	127.5%
Ratio to Revenue	0.8%	1.6%		

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

FY21 Full Year	Initial Forecasts	Revised Forecasts	Change from FY21
	FY22 Full Year	FY22 Full Year	Change (%)
1,296.2	1,443.0	1,529.0	18.0%
258.8	260.0	264.4	2.2%
20.0%	18.0%	17.3%	
537.5	644.2	680.8	26.7%
41.5%	44.6%	44.5%	
315.2	339.9	365.3	15.9%
24.3%	23.6%	23.9%	
66.3	74.4	80.2	21.0%
5.1%	5.2%	5.2%	
110.1	118.5	124.2	12.8%
8.5%	8.2%	8.1%	
8.4	6.0	14.1	68.2%
0.6%	0.4%	0.9%	

## 6. Per Share Information

	FY21 APR. - SEP.	FY22 APR. - SEP.
The number of shares issued (thousand)	1,861,787	1,835,851
Treasury Shares (thousand)	8,904	13,238
The number of shares issued after deducting Treasury Shares (thousand)	1,852,882	1,822,613
Earnings per share (yen)	38.65	52.87
Earnings per share (yen) core basis	53.30	65.78
Dividend per share (yen)	25	30

- The numbers of shares stated in the business report are presented by disregarding any number of shares less than the specified units.

FY21 Full Year
1,835,851
8,777
1,827,073
67.08
103.03
50

## Initial Forecasts Revised Forecasts

Initial Forecasts	Revised Forecasts
FY22 Full Year	FY22 Full Year
113.84	113.84
122.05	122.05
60	60

## 7. Investment in Property, Plant and Equipment

### Depreciation/Amortisation

Unit: B¥

	FY21 APR. - SEP.	FY22 APR. - SEP.	Change	Change (%)
Investment in Property, Plant and Equipment	13.0	17.5	4.5	34.5%
Depreciation (PP&E)	19.9	19.8	-0.1	-0.6%
Amortisation of Intangible Assets (incl. software, etc.)	17.2	40.0	22.8	132.5%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

FY21 Full Year
30.2
40.1
39.6

FY21 Full Year	Initial Forecasts	Revised Forecasts	Change from FY21
	FY22 Full Year	FY22 Full Year	Change (%)
30.2	39.0	37.0	22.7%
40.1	40.0	40.0	-0.1%
39.6	42.0	67.0	69.1%

8. Sales of major products

1) Global

Unit: B¥

	FY21 APR. - SEP.	FY22 APR. - SEP.	Change	Change (%)
XTANDI	267.6	332.0	64.4	24.1%
United States	141.1	174.9	33.7	23.9%
ex-US	126.5	157.2	30.7	24.3%
Japan	23.6	27.5	3.9	16.6%
Established Markets	83.9	99.2	15.3	18.3%
Greater China	3.6	6.0	2.4	66.2%
International Markets	15.4	24.4	9.0	58.6%
PADCEV	9.1	20.8	11.7	127.8%
Japan	-	4.0	4.0	-
United States	9.1	14.1	5.0	55.0%
Established Markets	-	2.6	2.6	-
International Markets	-	0.0	0.0	-
XOSPATA	16.5	23.5	7.0	42.5%
Japan	2.1	2.1	0.1	3.9%
United States	9.0	12.5	3.5	38.4%
Established Markets	4.1	5.6	1.5	35.4%
Greater China	1.0	2.4	1.4	138.9%
International Markets	0.3	0.8	0.6	235.9%
EVRENZO	1.4	1.5	0.1	8.7%
Japan	1.3	1.3	0.0	-1.9%
Established Markets	0.1	0.2	0.1	91.0%
International Markets	-	0.0	0.0	-
Betanis/Myrabetriq/BETMIGA	84.4	93.4	9.0	10.7%
Japan	18.7	17.5	-1.2	-6.6%
United States	42.0	47.4	5.3	12.7%
Established Markets	17.9	21.8	3.9	22.0%
Greater China	1.3	2.0	0.7	51.3%
International Markets	4.4	4.7	0.3	6.6%
Prograf	92.3	100.4	8.1	8.7%
Japan	19.7	18.5	-1.2	-6.1%
United States	4.8	5.1	0.4	8.0%
Established Markets	34.4	36.2	1.8	5.2%
Greater China	19.5	25.4	5.9	30.2%
International Markets	13.9	15.1	1.2	8.6%
Vesicare	12.8	8.1	-4.7	-36.6%

- Sales of products in Japan are shown in a gross sales basis.
- Established Markets: Europe, Canada, Australia
- Greater China: China, Hong Kong, Taiwan
- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.
- PADCEV (United States): Co-promotion revenue from Seagen
- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

	Initial Forecasts FY22 Full Year	Revised Forecasts FY22 Full Year	Change from FY21 Change (%)
	534.3	642.5	25.4%
	276.9	353.9	29.6%
	257.4	288.6	20.9%
	47.2	52.6	17.4%
	170.1	182.1	17.1%
	7.9	13.3	55.5%
	32.2	40.6	37.5%
	21.7	36.5	108.9%
	1.8	4.3	372.2%
	19.5	27.6	61.3%
	0.5	4.6	-
	-	0.0	-
	34.1	46.2	34.4%
	3.9	4.9	2.5%
	18.9	25.2	33.9%
	9.0	11.8	32.2%
	1.5	2.4	62.1%
	0.7	1.9	199.2%
	2.6	9.9	91.1%
	2.5	6.3	40.3%
	0.1	3.4	-
	-	0.2	-
	172.3	178.7	13.2%
	37.5	36.2	-11.7%
	87.2	90.2	19.5%
	36.7	40.6	22.0%
	2.9	3.6	31.0%
	8.1	8.1	14.4%
	185.4	190.7	8.1%
	38.2	35.7	-7.1%
	9.4	10.4	17.2%
	67.9	69.9	8.1%
	38.1	41.3	20.8%
	31.7	33.5	8.2%
	22.0	12.7	-30.2%

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	FY21 APR. - SEP.	FY22 APR. - SEP.	Change	Change (%)
XTANDI	23.6	27.5	3.9	16.6%
PADCEV	-	4.0	4.0	-
XOSPATA	2.1	2.1	0.1	3.9%
EVRENZO	1.3	1.3	0.0	-1.9%
Betanis	18.7	17.5	-1.2	-6.6%
Prograf (Including Graceptor)	19.7	18.5	-1.2	-6.1%
Vesicare	6.5	2.1	-4.4	-67.3%
Harnal	1.3	0.9	-0.4	-29.6%
Funguard	0.9	0.6	-0.3	-31.3%

<Main products>

Suglat [Family]	15.4	15.6	0.2	1.2%
Sujanu	6.3	6.3	0.0	-0.1%
Repatha	2.9	3.2	0.3	11.5%
Linzess	3.5	3.5	0.1	2.7%
BLINCYTO	2.9	3.8	0.8	29.1%
EVENITY	14.5	20.1	5.6	38.9%
Smyraf	1.2	1.3	0.0	3.9%
Vaccines	2.0	3.2	1.2	63.5%
Gonax	2.6	2.4	-0.1	-4.8%
Cimzia	5.6	5.8	0.2	2.9%
Myslee	3.6	3.0	-0.5	-15.3%
Total Rx Sales In Japanese market	129.7	132.0	2.3	1.8%

- Sales of products in Japan are shown in a gross sales basis.

FY21 Full Year	Initial Forecasts	Revised Forecasts	Change from FY21
	FY22 Full Year	FY22 Full Year	Change (%)
47.2	52.6	55.4	17.4%
1.8	4.3	8.3	372.2%
3.9	4.9	4.0	2.5%
2.5	6.3	3.5	40.3%
37.5	36.2	33.1	-11.7%
38.2	35.7	35.5	-7.1%
10.0	1.8	3.6	-63.6%
2.6	1.4	1.7	-35.6%
1.6	0.9	1.2	-29.2%
30.3	33.1	31.5	4.2%
12.5			
5.8			
6.9	7.8	7.3	5.3%
6.4			
31.4			
2.4	3.3	2.9	21.5%
5.1	8.6	7.6	48.6%
5.0	4.9	5.1	1.3%
11.2			
7.0	5.5	5.9	-16.4%
256.9	257.5	262.3	2.1%

## (2) United States

Unit: M\$

	FY21 APR. - SEP.	FY22 APR. - SEP.	Change	Change (%)
Revenue	2,461	2,448	-12	-0.5%
XTANDI	1,286	1,304	19	1.4%
PADCEV	83	105	22	26.9%
XOSPATA	82	93	11	13.3%
Myrbetriq	383	353	-30	-7.7%
Prograf	43	38	-5	-11.6%
Vesicare	8	3	-5	-67.0%
MYCAMINE	30	11	-19	-63.5%
AmBisome	68	58	-11	-15.7%
CRESEMBA	94	106	11	11.7%
Lexiscan	382	377	-5	-1.3%

	Initial Forecasts		Revised Forecasts		Change from FY21
	FY21 Full Year	FY22 Full Year	FY22 Full Year	FY22 Full Year	Change (%)
Revenue	4,782	5,368	4,968	4,968	3.9%
XTANDI	2,464	2,949	2,618	2,618	6.3%
PADCEV	174	230	230	230	32.3%
XOSPATA	168	210	185	185	9.8%
Myrbetriq	775	752	760	760	-2.0%
Prograf	84	87	80	80	-3.9%
Vesicare	15	11	6	6	-59.9%
MYCAMINE	48	18	20	20	-58.6%
AmBisome	135	143	106	106	-20.9%
CRESEMBA	194	209	217	217	11.7%
Lexiscan	725	739	724	724	-0.1%

## (3) Established Markets

Unit: M€

	FY21 APR. - SEP.	FY22 APR. - SEP.	Change	Change (%)
Revenue	1,203	1,299	96	8.0%
XTANDI	641	715	74	11.6%
PADCEV	-	19	19	-
XOSPATA	32	40	9	27.7%
EVRENZO	1	2	1	80.2%
BETMIGA	137	158	21	15.1%
Prograf	263	261	-2	-0.7%
Vesicare	23	21	-2	-9.5%
Omnice	35	33	-3	-7.4%
MYCAMINE	13	9	-4	-31.1%

	FY21 Full Year	FY22 Full Year	FY22 Full Year	Change (%)
Revenue	2,414	2,517	2,622	8.6%
XTANDI	1,303	1,349	1,429	9.7%
PADCEV	4	34	40	-
XOSPATA	69	88	86	23.8%
EVRENZO	1	25	9	947.0%
BETMIGA	281	301	321	14.3%
Prograf	520	518	527	1.3%
Vesicare	42	35	40	-5.5%
Omnice	67	64	65	-3.0%
MYCAMINE	22	15	16	-26.9%

- Established Markets: Europe, Canada, Australia



(4) Greater China

Unit: B¥

	FY21 APR. - SEP.	FY22 APR. - SEP.	Change	Change (%)
Revenue	33.1	45.0	12.0	36.2%
XTANDI	3.6	6.0	2.4	66.2%
XOSPATA	1.0	2.4	1.4	138.9%
BETMIGA	1.3	2.0	0.7	51.3%
Prograf	19.5	25.4	5.9	30.2%
Vesicare	0.5	0.5	0.0	7.8%
Harnal	4.0	4.9	0.9	23.1%
MYCAMINE	1.3	1.7	0.3	24.5%
Feburic	1.4	1.7	0.4	28.7%

- Greater China: China, Hong Kong, Taiwan

FY21 Full Year	Initial Forecasts	Revised Forecasts	Change from FY21
	FY22 Full Year	FY22 Full Year	Change (%)
66.3	74.4	80.2	21.0%
7.9	13.3	12.3	55.5%
1.5	2.4	2.5	62.1%
2.9	3.6	3.8	31.0%
38.1	41.3	46.1	20.8%
1.0	1.0	1.1	4.7%
8.2	8.0	8.5	3.5%
2.9	1.4	2.1	-28.8%
2.9	2.8	3.1	8.1%

(5) International Markets

Unit: B¥

	FY21 APR. - SEP.	FY22 APR. - SEP.	Change	Change (%)
Revenue	55.3	63.3	8.0	14.5%
XTANDI	15.4	24.4	9.0	58.6%
PADCEV	-	0.0	0.0	-
XOSPATA	0.3	0.8	0.6	235.9%
EVRENZO	-	0.0	0.0	-
BETMIGA	4.4	4.7	0.3	6.6%
Prograf	13.9	15.1	1.2	8.6%
Vesicare	1.8	2.2	0.3	18.7%
Harnal	8.1	8.9	0.8	10.4%
MYCAMINE	3.6	2.9	-0.7	-19.9%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

FY21 Full Year	Initial Forecasts	Revised Forecasts	Change from FY21
	FY22 Full Year	FY22 Full Year	Change (%)
110.1	118.5	124.2	12.8%
32.2	40.6	44.3	37.5%
-	0.0	0.1	-
0.7	1.9	2.0	199.2%
-	0.2	0.3	-
8.1	8.1	9.2	14.4%
31.7	33.5	34.4	8.2%
3.7	3.9	4.3	14.2%
16.1	17.8	17.0	5.2%
6.1	6.2	5.7	-7.0%

## 9. Consolidated statements of financial position

Unit: B¥

	FY21 End	FY22 Q2 End	Change
<b>Assets</b>	<b>2,332.4</b>	<b>2,583.7</b>	<b>251.3</b>
<b>Non-current assets</b>	<b>1,409.0</b>	<b>1,524.5</b>	<b>115.5</b>
Property, plant and equipment	269.0	280.6	11.5
Goodwill	303.0	353.1	50.1
Intangible assets	623.4	653.6	30.2
Trade and other receivables	29.8	26.7	-3.1
Investments accounted for using equity method	10.0	14.3	4.3
Deferred tax assets	72.3	96.5	24.1
Other financial assets	91.8	88.0	-3.9
Other non-current assets	9.5	11.8	2.3
<b>Current assets</b>	<b>923.4</b>	<b>1,059.1</b>	<b>135.8</b>
Inventories	153.1	168.6	15.6
Trade and other receivables	382.5	452.5	70.0
Income tax receivable	21.5	11.0	-10.5
Other financial assets	21.3	31.9	10.6
Other current assets	29.0	34.0	5.0
Cash and cash equivalents	316.0	361.1	45.1

Unit: B¥

	FY21 End	FY22 Q2 End	Change
<b>Equity and Liabilities</b>	<b>2,332.4</b>	<b>2,583.7</b>	<b>251.3</b>
<b>Equity</b>	<b>1,460.3</b>	<b>1,649.5</b>	<b>189.2</b>
<b>Equity attributable to owners of the parent</b>	<b>1,460.3</b>	<b>1,649.5</b>	<b>189.2</b>
Share capital	103.0	103.0	-
Capital surplus	179.5	180.1	0.7
Treasury shares	-13.9	-23.3	-9.4
Retained earnings	944.3	1,003.6	59.3
Other components of equity	247.5	386.1	138.6
<b>Liabilities</b>	<b>872.1</b>	<b>934.1</b>	<b>62.1</b>
<b>Non-current liabilities</b>	<b>184.7</b>	<b>172.7</b>	<b>-11.9</b>
Trade and other payables	0.7	5.0	4.3
Deferred tax liabilities	5.8	6.1	0.3
Retirement benefit liabilities	37.2	36.9	-0.3
Provisions	5.8	3.7	-2.2
Other financial liabilities	95.9	82.4	-13.5
Other non-current liabilities	39.2	38.6	-0.6
<b>Current liabilities</b>	<b>687.4</b>	<b>761.4</b>	<b>74.0</b>
Trade and other payables	130.7	146.5	15.8
Income tax payable	32.4	26.2	-6.1
Provisions	16.6	14.0	-2.6
Other financial liabilities	185.0	205.6	20.6
Other current liabilities	322.8	369.0	46.3

10. Employees

Number of employees

	FY21 2Q End	FY22 2Q End
Total	15,133	14,414

FY21 4Q End
14,522

11. Shareholders

	FY21 2Q End	FY22 2Q End
Banks	38.0%	39.1%
Securities	5.4%	4.4%
Other companies	3.1%	3.1%
Foreign companies	44.9%	44.9%
Individuals and others	8.4%	8.4%
Treasury Stock*	0.1%	0.0%

\* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust.

## [Three months ended September 30, 2022]

### 1. Consolidated Results (Full Basis)

Unit: B¥

	FY22			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	381.8	17.1%	380.4	16.9%
Cost of sales	88.9	42.8%	62.8	0.4%
Ratio to Revenue	23.3%		16.5%	
Gross profit	292.9	11.0%	317.6	20.8%
SG&A expenses	153.4	11.9%	154.6	15.9%
Ratio to Revenue	40.2%		40.6%	
XTANDI co-promotion fee in United States	43.1	25.1%	46.5	27.1%
Personnel expenses	51.2	4.5%	53.6	14.0%
Advertising and Sales Promotion and Other	59.1	10.1%	54.4	9.4%
R&D expenses	74.0	26.9%	65.2	7.3%
Ratio to Revenue	19.4%		17.1%	
Amortisation of intangible assets	10.7	80.2%	9.2	43.7%
Gain on divestiture of intangible assets	0.2	-	0.0	-
Share of profit (loss) of investments accounted for using equity method	0.3	19.8%	1.4	-
Other income	16.3	-	0.2	-91.4%
Net foreign exchange gains	14.1	-	-	-100.0%
Fair value remeasurements on contingent consideration	1.5	-	0.1	-
Other expense	38.4	41.7%	3.6	-67.2%
Impairment losses	22.0	-15.4%	0.7	-
Restructuring costs	0.0	-99.1%	1.1	-43.9%
Fair value remeasurements on contingent consideration	15.8	-	0.1	-98.8%
Operating profit	33.1	-8.2%	86.7	60.4%
Ratio to Revenue	8.7%		22.8%	
Finance income	0.9	-36.3%	3.6	725.8%
Finance expenses	2.4	39.6%	1.5	20.2%
Profit before tax	31.7	-11.6%	88.8	66.7%
Ratio to Revenue	8.3%		23.3%	
Income tax expense	6.9	33.5%	17.2	39.3%
Profit	24.8	-19.1%	71.6	75.0%
Ratio to Revenue	6.5%		18.8%	
Comprehensive income	134.4	271.2%	109.3	222.7%

2. Consolidated Results (Core Basis)

Unit: B¥

		FY22			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		381.8	17.1%	380.4	16.9%
Cost of sales		88.9	42.8%	62.8	0.4%
	Ratio to Revenue	23.3%		16.5%	
Gross profit		292.9	11.0%	317.6	20.8%
SG&A expenses		153.4	11.9%	154.6	15.9%
	Ratio to Revenue	40.2%		40.6%	
XTANDI co-promotion fee in United States		43.1	25.1%	46.5	27.1%
Personnel expenses		51.2	4.5%	53.6	14.0%
Advertising and Sales Promotion and Other		59.1	10.1%	54.4	9.4%
R&D expenses		74.0	26.9%	65.2	7.3%
	Ratio to Revenue	19.4%		17.1%	
Amortisation of intangible assets		10.7	80.2%	9.2	43.7%
Gain on divestiture of intangible assets		0.2	-	0.0	-
Share of profit (loss) of investments accounted for using equity method		0.3	19.8%	1.4	-
Operating profit		55.3	-12.0%	90.1	44.2%
	Ratio to Revenue	14.5%		23.7%	
Finance income		0.9	-36.3%	3.6	725.8%
Finance expenses		2.4	39.6%	1.5	20.2%
Profit before Tax		53.8	-14.0%	92.1	49.5%
	Ratio to Revenue	14.1%		24.2%	
Income tax expense		8.0	-40.1%	18.0	48.5%
Profit		45.8	-6.9%	74.1	49.7%
	Ratio to Revenue	12.0%		19.5%	

### 3. Revenue by Region

Unit: B¥

		FY22			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		381.8	17.1%	380.4	16.9%
Japan		66.8	-1.0%	66.5	5.5%
Ratio to Revenue		17.5%		17.5%	
United States		160.9	20.4%	167.4	22.7%
Ratio to Revenue		42.1%		44.0%	
Established Markets		88.7	13.7%	91.4	15.2%
Ratio to Revenue		23.2%		24.0%	
Greater China		23.2	41.0%	21.9	31.5%
Ratio to Revenue		6.1%		5.7%	
International Markets		31.8	14.5%	31.5	14.6%
Ratio to Revenue		8.3%		8.3%	
Others		10.4	273.9%	1.7	-32.8%
Ratio to Revenue		2.7%		0.4%	

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

### 4. Investment in Property, Plant and Equipment

#### Depreciation/Amortisation

Unit: B¥

	FY22			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Investment in Property, Plant and Equipment	11.7	125.9%	5.8	-25.5%
Depreciation (PP&E)	9.8	-0.8%	9.9	-0.4%
Amortisation of Intangible Assets (incl. software, etc.)	27.0	228.9%	12.9	44.1%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

		FY22			
		APR.-JUN.	Change	JUL.-SEP.	Change
		(Quarterly)	(%)	(Quarterly)	(%)
XTANDI		162.4	22.2%	169.6	25.9%
	United States	83.9	22.7%	90.9	25.0%
	ex-US	78.5	21.6%	78.7	27.0%
	Japan	14.1	17.4%	13.4	15.9%
	Established Markets	47.9	11.8%	51.3	25.0%
	Greater China	3.6	90.2%	2.4	40.0%
	International Markets	12.9	65.2%	11.6	51.9%
PADCEV		10.6	151.6%	10.2	107.6%
	Japan	2.0	-	2.0	-
	United States	7.3	74.8%	6.8	38.1%
	Established Markets	1.2	-	1.4	-
	International Markets	-	-	0.0	-
XOSPATA		10.5	26.3%	13.0	58.8%
	Japan	1.1	5.7%	1.0	2.0%
	United States	5.9	29.5%	6.5	47.4%
	Established Markets	2.7	31.2%	3.0	39.3%
	Greater China	0.5	-12.7%	2.0	296.5%
	International Markets	0.3	170.0%	0.5	300.1%
EVRENZO		0.7	19.3%	0.8	0.6%
	Japan	0.7	8.1%	0.6	-10.9%
	Established Markets	0.1	-	0.1	29.9%
	International Markets	-	-	0.0	-
Betanis/Myrabetriq/BETMIGA		47.9	9.0%	45.5	12.5%
	Japan	9.3	-5.0%	8.2	-8.4%
	United States	24.7	8.3%	22.7	17.9%
	Established Markets	10.6	24.6%	11.2	19.6%
	Greater China	1.0	46.8%	1.0	56.2%
	International Markets	2.3	5.7%	2.4	7.5%
Prograf		51.8	14.6%	48.6	3.1%
	Japan	9.6	-6.0%	8.8	-6.3%
	United States	2.5	20.3%	2.6	-1.7%
	Established Markets	18.4	13.4%	17.8	-2.1%
	Greater China	13.6	41.1%	11.8	19.6%
	International Markets	7.7	9.5%	7.4	7.7%
Vesicare		4.0	-45.4%	4.0	-24.6%

- Sales of products in Japan are shown in a gross sales basis.

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Seagen

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	FY22			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
XTANDI	14.1	17.4%	13.4	15.9%
PADCEV	2.0	-	2.0	-
XOSPATA	1.1	5.7%	1.0	2.0%
EVRENZO	0.7	8.1%	0.6	-10.9%
Betanis	9.3	-5.0%	8.2	-8.4%
Prograf (Including Gracaptor)	9.6	-6.0%	8.8	-6.3%
Vesicare	1.2	-73.9%	0.9	-52.2%
Harnal	0.5	-31.7%	0.5	-27.4%
Funguard	0.3	-29.0%	0.3	-33.5%

<Main products>

Suglat [Family]	8.0	2.1%	7.5	0.3%
Sujanu	3.3	2.0%	3.1	-2.3%
Repatha	1.6	12.2%	1.6	10.8%
Linzess	1.8	3.9%	1.7	1.4%
BLINCYTO	1.8	29.2%	2.0	29.0%
EVENITY	10.0	42.1%	10.1	35.9%
Smyraf	0.6	0.5%	0.6	7.7%
Vaccines	0.0	0.0%	3.2	63.2%
Gonax	1.3	-1.3%	1.2	-8.3%
Cimzia	3.0	4.2%	2.8	1.6%
Myslee	1.6	-14.5%	1.5	-16.1%
<b>Total Rx Sales In Japanese market</b>	<b>66.4</b>	<b>-0.9%</b>	<b>65.6</b>	<b>4.7%</b>

- Sales of products in Japan are shown in a gross sales basis.



## (2) United States

		FY22			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		1,240	1.5%	1,209	-2.5%
	XTANDI	647	3.5%	657	-0.5%
	PADCEV	57	47.5%	49	9.3%
	XOSPATA	46	9.3%	47	17.4%
	Myrbetriq	190	-8.6%	163	-6.7%
	Prograf	19	1.5%	19	-21.9%
	Vesicare	0	-119.1%	3	-47.8%
	MYCAMINE	6	-59.6%	5	-66.9%
	AmBisome	29	-4.9%	29	-24.3%
	CRESEMBA	53	15.5%	53	8.2%
	Lexiscan	194	-1.1%	183	-1.5%

## (3) Established Markets

		FY22			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		642	8.7%	656	7.3%
	XTANDI	347	6.8%	369	16.4%
	PADCEV	9	-	10	-
	XOSPATA	19	25.3%	21	29.9%
	EVRENZO	0	-	1	22.3%
	BETMIGA	77	19.1%	80	11.6%
	Prograf	133	8.4%	128	-8.7%
	Vesicare	11	2.1%	9	-20.3%
	Omnice	17	0.4%	16	-14.4%
	MYCAMINE	5	-24.3%	4	-39.0%

- Established Markets: Europe, Canada, Australia

## (4) Greater China

Unit: B¥

		FY22			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		23.2	41.0%	21.9	31.5%
	XTANDI	3.6	90.2%	2.4	40.0%
	XOSPATA	0.5	-12.7%	2.0	296.5%
	BETMIGA	1.0	46.8%	1.0	56.2%
	Prograf	13.6	41.1%	11.8	19.6%
	Vesicare	0.3	4.2%	0.3	12.2%
	Harnal	2.4	20.3%	2.5	26.0%
	MYCAMINE	0.8	35.8%	0.8	14.8%
	Feburic	0.8	35.0%	0.9	23.4%

- Greater China: China, Hong Kong, Taiwan

## (5) International Markets

Unit: B¥

		FY22			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		31.8	14.5%	31.5	14.6%
	XTANDI	12.9	65.2%	11.6	51.9%
	PADCEV	-	-	0.0	-
	XOSPATA	0.3	170.0%	0.5	300.1%
	EVRENZO	-	-	0.0	-
	BETMIGA	2.3	5.7%	2.4	7.5%
	Prograf	7.7	9.5%	7.4	7.7%
	Vesicare	1.1	22.9%	1.1	15.0%
	Harnal	4.2	-3.3%	4.8	26.1%
	MYCAMINE	1.4	-13.0%	1.5	-25.5%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

## R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Oct 2022

Underlined items indicate changes from the previous announcement in Aug 2022.

### XTANDI and Strategic products (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enzalutamide MDV3100 (XTANDI)	Small molecule	Androgen receptor inhibitor	Metastatic castration-sensitive prostate cancer	China P-III	Pfizer	
			Non-metastatic castration-sensitive prostate cancer	P-III		
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, previously untreated (first line; <u>cisplatin-ineligible</u> , combo with pembrolizumab)	<u>US</u> <u>Submitted (Oct 2022)</u>	In-house [Co-development with Seagen]	
			Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	P-III		
			Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III		
			Other solid tumors	P-II		
			Non-muscle-invasive bladder cancer	P-I		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-I		
			Acute myeloid leukemia in pediatric patients	P-III		

**XTANDI and Strategic products (2/2)**

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
zolibetuximab IMAB362	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
fezolinetant ESN364	Small molecule	NK3 receptor antagonist	Vasomotor symptoms associated with menopause	US <u>Filed (Aug 2022)</u> Europe <u>Filed (Sep 2022)</u> China P-III Japan P-II	In-house (Ogeda)	
resamirigene bilparovect AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

**Updates from the previous announcement (Aug 2022):**

**enfortumab vedotin:** sBLA submitted in US in Oct 2022 for unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy in the first-line setting.

**roxadustat:** Discontinued the development for chemotherapy-induced anemia in Phase 2 for Astellas-owned territories due to the re-evaluation of the program business case.

**fezolinetant:** Filed in US in Aug 2022 and Europe in Sep 2022 for moderate to severe vasomotor symptoms associated with menopause.

Projects with Focus Area approach (1/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Immunology	ASP9801	Oncolytic virus	Oncolytic virus carrying IL-7 and IL-12	Cancer	P-I	Tottori University [Discovered through collaborative research]	
	ASP7517	Cell therapy (artificial adjuvant vector cells)	WT1 loaded artificial adjuvant vector cell	Acute myeloid leukemia and myelodysplastic syndrome	P-II	RIKEN [Discovered through collaborative research]	
				Solid tumor	P-I		
	ASP0739	Cell therapy (artificial adjuvant vector cells)	NY-ESO-1 loaded artificial adjuvant vector cell	Cancer	P-I	RIKEN [Discovered through collaborative research]	
	ASP1570	Small molecule	DGKζ inhibitor	Cancer	P-I	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]	
ASP2074	Antibody	Bispecific antibody	Cancer	P-I	In-house		
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelium cells	Geographic atrophy secondary to age-related macular degeneration, Stargardt disease	P-I	In-house (Ocata Therapeutics)	
Mitochondria	bocidelpar ASP0367/MA-0211	Small molecule	PPARδ modulator	Primary mitochondrial myopathies	P-II	In-house (Mitobridge)	
				Duchenne muscular dystrophy	P-I		
	ASP8731/ML-0207	Small molecule	BACH1 inhibitor	Sickle cell disease	P-I	In-house (Mitobridge)	

**Projects with Focus Area approach (2/2)**

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
Genetic regulation	resamirigene bilparvovec AT132 ***	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes Therapeutics)	
Targeted Protein Degradation	ASP3082	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
(Other projects with Focus Area approach)	FX-322	Small molecule	Inner ear progenitor cell activator (combination of GSK-3 inhibitor and HDAC inhibitor)	Sensorineural hearing loss	P-II	Frequency Therapeutics	Astellas has rights in Ex-US markets
	ASP0598	Recombinant protein	Recombinant human heparin-binding epidermal growth factor-like growth factor	Chronic tympanic membrane perforation	P-I	Auration Biotech	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

\*\*\* AT132 is also listed in "XTANDI and Strategic products".

**Updates from the previous announcement (Aug 2022):**

ASP2074: Entered into Phase 1 for cancer.

## Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
mirabegron YM178	Small molecule	$\beta_3$ receptor agonist	Neurogenic detrusor overactivity in pediatric patients	Europe P-III	In-house	
			Overactive bladder in pediatric patients	Europe P-III		
peficitinib ASP015K	Small molecule	JAK inhibitor	Rheumatoid arthritis	China <u>Filed (Aug 2022)</u>	In-house	
isavuconazole	Small molecule	Azole antifungal	Invasive aspergillosis and mucormycosis in pediatric patients	US P-II	Basilea	
ASP8062	Small molecule	GABA <sub>B</sub> receptor positive allosteric modulator	Alcohol use disorder	P-I	In-house	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

### Updates from the previous announcement (Aug 2022):

**peficitinib:** Filed in China in Aug 2022 for Rheumatoid arthritis.

## Rx+ Program

As of Oct 2022

Underlined items indicate changes from the previous announcement in Aug 2022.

Category	Program	Concept	Status*	Partner	Remarks
Digital health Other services	Fit-eNce	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise	<u>Under feasibility study</u>		
	Fit-eNce Home	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise at home	<u>Under feasibility study</u>		
	BlueStar	Digital therapeutics for adults with diabetes	Under clinical trial preparation	Welldoc	
Drug-device combination	pudexacianinium chloride ASP5354	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III		
		<u>Visualization and localization of lymph nodes in patients with breast cancer or melanoma undergoing lymphatic mapping</u>	<u>P-II</u>		

\* The list shows the most advanced stage if the stages are different depending on the region.

### Updates from the previous announcement (Aug 2022):

**Game application for exercise support:** Discontinued the development.

**Fit-eNce:** Changed status to feasibility study.

**Fit-eNce Home:** Changed status to feasibility study.

**pudexacianinium chloride (ASP5354):** Entered into Phase 2 for visualization and localization of lymph nodes in patients with breast cancer or melanoma undergoing lymphatic mapping.